CMC ICOS Biologics, Inc., a clinical and commercial manufacturer of monoclonal antibodies and other therapeutic proteins, and Trellis Bioscience LLC, a private, therapeutic antibody company, have entered into a manufacturing agreement for the process development and production of two of Trellis’ monoclonal antibodies (mAbs). Trellis is developing human mAb therapies for bacterial and viral infections, and cancer indications, and has selected CMC Biologics to work with on two of these products...